FKBP52/FKBP4 Antibody

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line. PVDF membrane was probed with 0.3 µg/mL of Human/Mouse/Rat FKBP52 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF4095) followed by HRP-conjugated Anti‑Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for FKBP52 at approximately 52 kDa (as indicated). This experiment was conducted using Immunoblot Buffer Group 2.

Effect of low-dose tacrolimus, L-NAME or mifepristone and their combination formulations on the levels of expression and cellular localization of FKBP52 and PGR in HTR-8/SVneo cells. (A) Representative confocal fluorescent microscope images of monolayers of confluent HTR-8/SVneo cells treated for 24 h with low-dose tacrolimus (10 ng/mL), L-NAME or a combination of both. Cells were stained with antibodies to PGR (red channel) and FKBP52 (green channel) and cell images were captured and analyzed for their fluorescent intensity using Quorum Wave Effects Spinning disc confocal microscope. Nuclei were counterstained with DAPI (blue channel) and the colocalization of PGR and FKBP52 appears as yellow on the overlay images. (B) Histogram depicting differences in the intensity of colocalization of PGR and FKBP52 (yellow channel) showing significant effect of low-dose tacrolimus on the expression of the PGR-FKBP52 complex in treated HTR-8/SVneo cells. (C) Representative WB images and associated histograms of the expression levels of FKBP52 protein in the tacrolimus- and L-NAME-treated HTR-8/SVneo cells. Note the statistically significant effects (p < 0.001) of tacrolimus in antagonizing the suppressive actions of L-NAME and those of mifepristone on the protein expression of FKBP52 in the HTR-8/SVneo cells. Data in (B,C) are represented as the mean with error bars representing S.D. Scale bars in A = 15 μm. Mifepristone was used to determine the mode of action of tacrolimus in potentiating the PGR signaling in HTR-8/SVneo cells. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35955565), licensed under a CC-BY license. Not internally tested by R&D Systems.

Effect of low-dose tacrolimus, L-NAME or mifepristone and their combination formulations on the levels of expression and cellular localization of FKBP52 and PGR in HTR-8/SVneo cells. (A) Representative confocal fluorescent microscope images of monolayers of confluent HTR-8/SVneo cells treated for 24 h with low-dose tacrolimus (10 ng/mL), L-NAME or a combination of both. Cells were stained with antibodies to PGR (red channel) and FKBP52 (green channel) and cell images were captured and analyzed for their fluorescent intensity using Quorum Wave Effects Spinning disc confocal microscope. Nuclei were counterstained with DAPI (blue channel) and the colocalization of PGR and FKBP52 appears as yellow on the overlay images. (B) Histogram depicting differences in the intensity of colocalization of PGR and FKBP52 (yellow channel) showing significant effect of low-dose tacrolimus on the expression of the PGR-FKBP52 complex in treated HTR-8/SVneo cells. (C) Representative WB images and associated histograms of the expression levels of FKBP52 protein in the tacrolimus- and L-NAME-treated HTR-8/SVneo cells. Note the statistically significant effects (p < 0.001) of tacrolimus in antagonizing the suppressive actions of L-NAME and those of mifepristone on the protein expression of FKBP52 in the HTR-8/SVneo cells. Data in (B,C) are represented as the mean with error bars representing S.D. Scale bars in A = 15 μm. Mifepristone was used to determine the mode of action of tacrolimus in potentiating the PGR signaling in HTR-8/SVneo cells. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35955565), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu, Mu, Rt
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

FKBP52/FKBP4 Antibody Summary

• Immunogen: E. coli-derived recombinant human FKBP52
  Met1-Ala459
  Accession # Q02790
• Specificity: Detects endogenous human, mouse and rat FKBP52 in Western blots. In Western blots, this antibody does not cross-react with recombinant human FKBP12, FKBP13, FKBP38 or FKBP51.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FKBP4
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.3 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FKBP52/FKBP4 Antibody

• 51 kDa FK506-binding protein
• 52 kDa FKBP
• 59 kDa immunophilin
• EC 5.2.1.8
• FK506 binding protein 4, 59kDa
• FK506-binding protein 4 (59kD)
• FK506-binding protein 4
• FKBP4
• FKBP-4
• FKBP51
• FKBP52
• FKBP-52
• FKBP52T-cell FK506-binding protein, 59kD
• FKBP59
• FKBP5952 kDa FK506-binding protein
• HBI
• HSP binding immunophilin
• Hsp56
• HSP-binding immunophilin
• Immunophilin FKBP52
• p52
• p59
• peptidyl-prolyl cis-trans isomerase FKBP4
• peptidylprolyl cis-trans isomerase
• PPIase FKBP4
• PPIase
• rotamase

Background

FK506 binding protein, 52 kDa molecular weight (FKBP52), also called FKBP4, is a peptidyl-prolyl isomerase that catalyzes the transition between cis- and trans- proline residues critical for proper folding of proteins. It associates with HSP90 complexes that are critical for the proper folding of steroid receptors. FKBP52 knockout mice have abnormal reproductive organ development due to disruption of androgen receptor folding.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FKBP52/FKBP4 Antibody (AF4095)(1)

Publication using AF4095

• AJH Albaghdadi, K Coyle, FWK Kan Low-Dose Tacrolimus Promotes the Migration and Invasion and Nitric Oxide Production in the Human-Derived First Trimester Extravillous Trophoblast Cells In Vitro International Journal of Molecular Sciences, 2022-07-29;23(15):. 2022-07-29 [PMID: 35955565] (Western Blot, Human)

Bioinformatics

• Gene Symbol: FKBP4
• Uniprot:
  • Q02790()